Benz-de Bretagne Isabelle, Respaud Renaud, Vourc'h Patrick, Halimi Jean-Michel, Caille Agnès, Hulot Jean-Sébastien, Andres Christian R, Le Guellec Chantal
CHRU de Tours, Laboratoire de Biochimie et Biologie Moléculaire, Tours, France.
J Biomed Biotechnol. 2011;2011:498757. doi: 10.1155/2011/498757. Epub 2011 Mar 14.
MRP2 encoded by ABCC2 gene is involved in the secretion of numerous drugs and endogenous substrates. Patients with Dubin-Johnson syndrome due to mutation in ABCC2 gene have elevated urinary coproporphyrin ratio (UCP I/(I + III)). Here we investigated whether this ratio could serve as a biomarker of MRP2 function. Phenotype-genotype relationships were studied in 74 healthy subjects by measuring individual UCP I/(I + III) ratio obtained on 24-hour urine and by analyzing five common SNPs in ABCC2 gene. The UCP I/(I + III) ratio varied from 14.7% to 46.0% in our population. Subjects with 3972TT genotype had a higher ratio (P = .04) than those carrying the C allele. This higher UCP I/(I + III) ratio was correlated with a higher level of isomer I excretion. This study provides a proof of concept that UCP I/(I + III) ratio can be used as a biomarker of MRP2 function in clinical studies as it provides quantitative information about the in vivo activity of MRP2 in a given patient.
由ABCC2基因编码的多药耐药相关蛋白2(MRP2)参与多种药物和内源性底物的分泌。因ABCC2基因突变导致的杜宾-约翰逊综合征患者尿中粪卟啉比率(UCP I/(I + III))升高。在此,我们研究了该比率是否可作为MRP2功能的生物标志物。通过测量74名健康受试者24小时尿液中的个体UCP I/(I + III)比率,并分析ABCC2基因中的五个常见单核苷酸多态性(SNP),研究了表型-基因型关系。在我们的研究人群中,UCP I/(I + III)比率在14.7%至46.0%之间变化。3972TT基因型的受试者比携带C等位基因的受试者具有更高的比率(P = .04)。这种较高的UCP I/(I + III)比率与异构体I排泄水平较高相关。本研究提供了一个概念验证,即UCP I/(I + III)比率可在临床研究中用作MRP2功能的生物标志物,因为它提供了关于特定患者体内MRP2活性的定量信息。